Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates significant symptom reduction in ankylosing spondylitis with secukinumab, indicating effective intervention.
Secukinumab at a subcutaneous dose of 150 mg, with either subcutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16. Secukinumab at a subcutaneous dose of 75 mg resulted in significant improvement only with a higher intravenous loading dose. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT01358175 and NCT01649375.).
No takes yet. Share an insight, caveat, or question.
Baeten et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: